Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

被引：55

作者：

Hanquet, Germaine ^{[1
,2
]}

Krizova, Pavla ^{[3
]}

Dalby, Tina ^{[4
]}

Ladhani, Shamez N. ^{[5
]}

Nuorti, J. Pekka ^{[6
,7
]}

Danis, Kostas ^{[8
]}

Mereckiene, Jolita ^{[9
]}

Knol, Mirjam J. ^{[10
]}

Winje, Brita A. ^{[11
]}

Ciruela, Pilar ^{[12
,13
]}

de Miguel, Sara ^{[14
]}

Eugenia Portillo, Maria ^{[15
]}

MacDonald, Laura ^{[16
]}

Morfeldt, Eva ^{[17
]}

Kozakova, Jana ^{[3
]}

Valentiner-Branth, Palle ^{[4
]}

Fry, Norman K. ^{[5
]}

Rinta-Kokko, Hanna ^{[7
]}

Varon, Emmanuelle ^{[18
]}

Corcoran, Mary ^{[19
]}

van der Ende, Arie ^{[20
]}

Vestrheim, Didrik F. ^{[11
]}

Munoz-Almagro, Carmen ^{[13
,21
,22
]}

Sanz, Juan-Carlos ^{[14
]}

Castilla, Jesus ^{[13
,23
]}

Smith, Andrew ^{[24
]}

Henriques-Normark, Birgitta ^{[25
,26
]}

Colzani, Edoardo ^{[27
]}

Pastore-Celentano, Lucia ^{[27
]}

Savulescu, Camelia ^{[1
]}

机构：

[1] Epiconcept, 25 Rue Titon, F-75011 Paris, France

[2] Antwerp Univ, Antwerp, Belgium

[3] Natl Inst Publ Hlth, Prague, Czech Republic

[4] Statens Serum Inst, Copenhagen, Denmark

[5] Publ Hlth England, London, England

[6] Tampere Univ, Tampere, Finland

[7] Finnish Inst Hlth & Welf, Helsinki, Finland

[8] Natl Publ Hlth Agcy, Sante Publ France, St Maurice, France

[9] Hlth Protect Surveillance Ctr, Dublin, Ireland

[10] Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands

[11] Norwegian Inst Publ Hlth, Oslo, Norway

[12] Publ Hlth Agcy Catalonia, Barcelona, Spain

[13] CIBER Epidemiol & Salud Publ, Madrid, Spain

[14] Gen Directorate Publ Hlth Madrid Reg, Madrid, Spain

[15] Navarra Hosp Complex IdiSNA, Pamplona, Spain

[16] Publ Hlth Scotland, Glasgow, Lanark, Scotland

[17] Publ Hlth Agcy Sweden, Stockholm, Sweden

[18] Ctr Rech Clin & Biol, Creteil, France

[19] Childrens Hlth Ireland CHI Temple St, Dublin, Ireland

[20] Acad Med Ctr, Amsterdam, Netherlands

[21] Hosp St Joan de Deu, Barcelona, Spain

[22] Univ Int Catalunya, Barcelona, Spain

[23] Publ Hlth Inst Navarra IdiSNA, Pamplona, Spain

[24] Univ Glasgow, Glasgow, Lanark, Scotland

[25] Karolinska Inst, Stockholm, Sweden

[26] Karolinska Univ Hosp, Solna, Sweden

[27] European Ctr Dis Prevent & Control, Stockholm, Sweden

来源：

EMERGING INFECTIOUS DISEASES | 2022年 / 28卷 / 01期

基金：

欧盟地平线“2020”;

关键词：

DISEASE; IMPACT; VACCINATION; CHILDREN; ENGLAND; WALES; PCV13;

D O I：

10.3201/eid2801.210734

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >= 65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution.Serotypes included in the 15-valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children <5 years of age and in persons >65 years of age in 2018. Non-PCV13 serotype increases reduced the overall effect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.

引用

页码：127 / 138

页数：12

共 50 条

[1] Pneumococcal immunization with conjugate vaccines: are 10-valent and 13-valent vaccines similar?
Esposito, Susanna
Principi, Nicola
[J]. FUTURE MICROBIOLOGY, 2019, 14 (11) : 921 - 923
[2] Pneumococcal immunization with conjugate vaccines - are 10-valent and 13-valent vaccines similar?
Vyse, Andrew
Theilacker, Christian
Sings, Heather
Fletcher, Mark
[J]. FUTURE MICROBIOLOGY, 2020, 15 (08) : 575 - 578
[3] The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease
Principi, Nicola
Esposito, Susanna
[J]. EXPERT REVIEW OF VACCINES, 2015, 14 (10) : 1359 - 1366
[4] Comparing the Impact of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease
Theilacker, Christian
Hilton, Betsy
Jiang, Qin
Gessner, Bradford D.
[J]. CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) : 1641 - 1642
[5] Comparing the Impact of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease Reply
Naucler, Pontus
Galanis, Ilias
Morfeldt, Eva
Darenberg, Jessica
Ortqvist, Ake
Henriques-Normark, Birgitta
[J]. CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) : 1642 - 1643
[6] A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
Patel, R.
Stoykova, B.
Lloyd, A. C.
Willingham, J.
Hollingsworth, R.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A428 - A428
[7] Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
Stephanie R Earnshaw
Cheryl L McDade
Giovanni Zanotti
Raymond A Farkouh
David Strutton
[J]. BMC Infectious Diseases, 12
[8] Cost-effectiveness of 2+1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
Earnshaw, Stephanie R.
McDade, Cheryl L.
Zanotti, Giovanni
Farkouh, Raymond A.
Strutton, David
[J]. BMC INFECTIOUS DISEASES, 2012, 12
[9] Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines
Tyo, Karen Richards
Rosen, Melissa M.
Zeng, Wu
Yap, Mabel
Pwee, Keng Ho
Ang, Li Wei
Shepard, Donald S.
[J]. VACCINE, 2011, 29 (38) : 6686 - 6694
[10] Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia
Urbancikova, Ingrid
Prymula, Roman
Goldblatt, David
Roalfe, Lucy
Prymulova, Karolina
Kosina, Pavel
[J]. VACCINE, 2017, 35 (38) : 5186 - 5193

← 1 2 3 4 5 →